Summary Between 1982 and 1991, 41 
Primary cerebral lymphoma (PCL) is a rare neoplasm accounting for approximately 0.7% of all lymphoma and less than 2% of all brain tumours (Henry et al., 1974; Levitt et al., 1980; Woodman et al., 1985; Murray et al., 1987; Hochberg & Miller, 1988) . The incidence of PCL is significantly increased in patients with severe immunodeficiency including acquired immunodeficiency syndrome (AIDS) (Snyder et al., 1983; Gill et al., 1985) . Recent reports indicate that the incidence of PCL is also increasing in apparently nonimmunodeficient subjects, although the reason for these observations remains obscure (Eby et al., 1988) . In contrast to other non Hodgkin's lymphomas (Canellos et al., 1987; Coiffer et al., 1989; Longo et al., 1991; Patte et al., 1991) , PCL has a poor prognosis in most of the series with treatment combining surgery with chemotherapy and/or radiotherapy (Murray et al., 1987; Hochberg & Miller, 1988; Berry et al., 1981; Letendre et al., 1982; Gonzales-Gonzales et al., 1983; Freeman et al., 1986) . However, intensive chemotherapy regimens including drugs that pass the bloodbrain barrier appear to give improved results in recently published trials (De Angelis et al., 1990; Neuwelt et al., 1991; De Angelis et al., 1992) . Neuwelt et al. (1991) have described a regimen containing high dose methotrexate (HDMTX) and two alkylating agents given wtih osmotic blood-brain barrier disruption which yields a projected 40% survival and at 3 years. De Angelis et al. (1992) have reported a regimen combining HDMTX, cytosine arabinoside and cranial irradiation which yields 35% survival at 4 years.
Since PCL is a rare neoplasm, most of the series include a limited number of patients and the optimal treatment remains to be defined. Furthermore, comparison of therapeutic results between studies is complicated by the differences in the clinical presentations of this disease and the lack of knowledge of prognostic factors. Several univariate analyses, most involving less than 30 patients, have identified prognostic factors for survival in patients with PCL ) Loeffler et al., 1985; Murray et al., 1986; Mendenhall et al., 1986; Pollack et al., 1989; Michalski et al., 1990) . Some of these prognostic factors are identical to those previously shown for aggressive lymphomas not involving the CNS, such as age, performance status at diagnosis, size of the lesion, and serum LDH levels.
Specific prognostic factors for PCL, such as confinement of the tumour to cerebral hemispheres and extension of the tumour outside the brain have also been reported (Murray et al., 1986; Loeffler et al., 1985; Pollack et al., 1989; Michalski et al., 1990) . Among therapeutic features, the dose of radiation (Murray et al., 1986; Berry & Simpson, 1981; Pollack et al., 1989; Brada et al., 1990) and treatment with chemotherapy (Pollack et al., 1989; Michalski et al., 1990; Shibamato et al., 1989) The three remaining patients were treated with radiotherapy only because of patient refusal. Relapses were evidenced by CT scan in 20 patients. Twelve (60%) of the 20 documented relapses occurred only at the primary brain site whereas eight (40%) patients had multifocal brain relapse.
Two patients (4%) experienced ocular relapse. None of the patients relapsed outside the central nervous system (CNS).
Methods
Statistical analyses were carried out according to the procedures of the BMDP package. The Chi square test was used to compare the distribution of the different parameters between the subgroups of patients. The survival curves were generated by the Kaplan-Meier method (Kaplan & Meier, 1958) . Survival times were measured from the date of the histological diagnosis of the lymphoma to the date of death or the date of the last follow-up of patients still alive. The log-rank test was used to compare the distribution of survival times in univariate analysis and to select statistically significant factors. Then, a multivariate analysis was performed using the Cox proportional hazard model (Cox, 1972) . Backwards regression selection procedure was used to identify the significant prognostic factors. Relative risks were expressed as the ratio of relative death rate into two groups (Oi/Ei, O:observed), E:expected). The relative risks of these prognostic factors were used to create an algorithm which made it possible to separate the patients into three distinct risk groups. Using the regression coefficinet estimated in the Cox model for each variables, covariate scores were calculated for each patient. These results were used to construct the theoretical survival in the three discriminant risk groups.
primary cerebral large cell lymphoma associated with a small lymphocytic lymphoma of lymph nodes and bone marrow (Table I) ; this patient died of PCL progression after chemotherapy while in complete remission of the small lymphocytic lymphoma.
Macroscopic complete and partial surgical resections were performed in four (10%) and 15 (37%) patients respectively. Twenty-two (53%) patients underwent only a tumour biopsy for diagnosis. Thirty-eight of the 41 patients (92%) received chemotherapy as first line therapy after surgery. Twentyseven of these received cranial radiotherapy after chemotherapy. The 11 remaining patients died during chemotherapy before the initiation of radiotherapy. Chemotherapy regimens given to these patients were as follows. The short arm of the LMB chemotherapy program (Patte et al., 1991) including five courses of chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone, cytosine-arabinoside, high dose methotrexate, seven intrathecal injections of methotrexate, two intrathecal injections of cytosine arabinoside) was given to all the patients under 50 years of age (n = 9). Patients over 70 (n = 5) received six courses of CTVP (cyclophosphamide 750 mg m-2 dl, pirarubicin 50 mg k-2 dl, teniposide 75 mg m-2 dl, methylprednisone 40 mg m-2 dl-3).
Before 1987, eight courses of the m/MBACOD regimen (high dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone) were given to the seven patients above 50 years of age (Canellos et al., 1987) . After 1987, all patients above 50, were included in the LNH87 protocol (n = 17) (Coiffier et al., 1989) . This program contained an induction chemotherapy sequence with either four courses of ACVBP (bleomycin, doxorubicin, cylcophos-
Results
With a median follow up of 30 months, the projected overall survival is 22% and the median survival is 20 months (Figure  1 ). Clinical and biological prognostic factors for survival were analysed (Table II) . Five parameters were found to have an unfavourable prognostic value: (a) non hemispheric tumour location i.e. involvement of corpus callosum or subcortical grey structures (P = 0.03), (b) age over 60 (P <0.01), (c) memory dysfunction (P<0.01), (d) initial performance status (PS) over 2 on the ECOG scale (P = 0.001) and (e) presence of a cerebrospinal fluid (CSF) protein level over 0.6 g 1-', at the diagnosis (P<0.001). The latter criterion was found to be the most significant unfavourable prognostic factor (Table II) . No differences for time to relapse, site of relapse or survival rates were observed according to the different surgical procedures or the total dose of radiation given to the whole brain (Table II) . Survival was not significantly different between the chemotherapy regimens, i.e. the LMB program, LNH87, m/MABCOD and CTVP (data not shown).
Significant (P<0.05) prognostic factors for survival were selected for the multivariate analysis (Table II) . Only CSF protein level, performance status and age were found to be independent determinants of survival (Table III) . The two remaining prognostic factors, i.e. hemispheric location and memory dysfunction were strongly correlated to both CSF protein level and performance status (P<0.01) and were thus eliminated by the regression procedure. The relative risks of performance status and age were similar in magnitude (relative risk (RR): 2.43 and 2.65) and close to half of (Table IV) . Covariate scores were calculated as indicated in materials and methods for the different combinations of the three parameters and usef for the construction of theoretical survival of the three risk groups. These three risk groups have a simulated median survival of 54, 20 and 4 months and include 25% (n = 10), 36% (n = 15) and 39% (n = 16) of the patients of this series respectively. The simulated and observed survival curves of these three risk groups are shown in Figure 2 . Months from diagnosis Figure 2 Curves 1,2,3 correspond to the observed survival in patients from risk group 1, 2 and 3. Curves A,B,C correspond to the theoretical survival of patients from risk group 1, 2 and 3 according to the model.
Discussion
The aim of this study was to determine independent prognostic factors for survival in PCL and to distinguish prognostic subgroups. This series includes 41 patients with non HIV PCL treated in our institution since 1982 and thus represents, given the low incidence of PCL, a relatively large group of PCL for a single institution. Survival in this series is comparable to that previously reported in the literature for PCL (Murray et al., 1987; Hochberg & Miller, 1988) . Our data confirm previous observations indicating that age, performance status, and hemispheric location of the tumour are prognostic factors in PCL (Murray et al., 1986; Mendenhall et al., 1986; Loeffler et al., 1985; Pollack et al., 1989; Michalski et al., 1990 (Byar et al., 1979) and renal cell carcinoma (Elson et al., 1988) and can be easily used for medical decision making.
The most favourable group, risk group 1, has a theoretical median survival of 54 months after the diagnosis whereas risk group 3 has a median survival of 4 months. These results point out that subgroups with a completely different prognosis can be identified among patients with PCL. Recently, a prognostic index has been reported in NHL using a database of 3273 patients (Shipp et al., 1992) . The classification of the 41 PCL patients of our series according to this prognostic index did not distinguish the subgroup of good prognosis (25% of the patients) described in our model (personal unpublished results), indicating that PCL could require a distinct prognostic index.
In this study, the same data were used to derive and verify the index; it will thus be interesting to test the value of this model in another large series of patients with PCL. Retrospective comparisons of different treatments for PCL could take such a model in account in order to analyse results between comparable subgroups of patients. These prognostic subgroups could also be considered for stratification in future clinical trials.
We have tried to analyse the role of the different therapeutic procedures in this series according to the prognostic index. These observations are of course only indicative since the effect of treatments can only be assessed in a prospective manner. Doses of radiotherapy over 50 Grays (Gy) have previously been associated with an improved survival compared to lower doses (Murray et al., 1986; Berry et al., 1983) . No correlation between the dose of radiotherapy and survival was observed in this series. Neither of the two patients who received such doses was alive 20 months after the diagnosis. Furthermore, among four long term (over 4 years diseasefree) survivors, three received less than 40 Gy to the whole brain. Also, all these patients belonged to risk group 1. This suggests that, at least for risk group 1, high doses of radiotherapy to the whole brain may not be necessary to achieve long term disease control. However, most relapses occurred at the primary brain site. It could be valuable to study radiotherapy protocols giving a high dose (> 50 Gy) to the tumour bed and a reduced dose to the whole brain in risk groups 2 and 3. The association of chemotherapy and radiotherapy after surgery has been reported to yield better results than radiotherapy alone (Pollack et al., 1989; Michalski et al., 1990; Shibamato et al., 1989 ) although this has not consistently been found (Murray et al., 1986 ). An important point is whether a reduction of chemotherapy intensity in patients over 60 years may be responsible for the worse survival in this subgroup. Most of the regimens used in these patients (see Materials and methods) included high dose methotrexate and/or ARA-C, two drugs previously reported to be highly efficient in PCL (Neuwelt et al., 1991; de Angelis et al., 1992) . Actually, no significant differences in terms of survival were observed between the different chemotherapy regimens used in this study, including CTVP (not shown) but the low number of patients in each subgroup limit the value of this observation. Furthermore, patients between 50 and 70 years old received the same chemotherapy regimens. It is thus unlikely that the correlation between age and prognostic is due to a reduction of treatment intensity in patients older than 60.
The radiotherapy and chemotherapy protocols used in this study are clearly unable to provide a long term tumour control in most of the patients not belonging to risk group 1. It is noteworthy that all the 5 year survivors belong to risk group 1, a subgroup of patients with 4 year survival of 57% which represents only 25% of our population. Only a small number of patients from risk group 2 and 3, if any, can achieve long term survival. These results indicate that patients from risk group 1 require different therapeutic procedures than patients from risk group 2 and 3 and that current treatments have a poor efficacy in patients who do not belong to risk group 1.
